{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:17:30Z","timestamp":1761895050619},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,3,30]],"date-time":"2010-03-30T00:00:00Z","timestamp":1269907200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1038\/nrclinonc.2010.31","type":"journal-article","created":{"date-parts":[[2010,3,30]],"date-time":"2010-03-30T05:37:06Z","timestamp":1269927426000},"page":"289-294","source":"Crossref","is-referenced-by-count":14,"title":["Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma"],"prefix":"10.1038","volume":"7","author":[{"given":"Heinz","family":"Ludwig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niklas","family":"Zojer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,3,30]]},"reference":[{"key":"BFnrclinonc201031_CR1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3322\/caac.20006","volume":"59","author":"A Jemal","year":"2009","unstructured":"Jemal, A. et al. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225\u2013249 (2009).","journal-title":"CA Cancer J. Clin."},{"key":"BFnrclinonc201031_CR2","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1093\/annonc\/mdi098","volume":"16","author":"P Boyle","year":"2005","unstructured":"Boyle, P. & Ferlay, J. Cancer incidence and mortality in Europe, 2004. Ann. Oncol. 16, 481\u2013488 (2005).","journal-title":"Ann. Oncol."},{"key":"BFnrclinonc201031_CR3","unstructured":"American Cancer Society. Detailed guide: multiple myeloma. What are the risk factors for multiple myeloma? Cancer Reference Information [ online ] (2010)."},{"key":"BFnrclinonc201031_CR4","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.3324\/haematol.2009.010066","volume":"94","author":"SY Kristinsson","year":"2009","unstructured":"Kristinsson, S. Y. et al. Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Hematologica 94, 1714\u20131720 (2009).","journal-title":"Hematologica"},{"key":"BFnrclinonc201031_CR5","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","volume":"111","author":"RA Kyle","year":"2008","unstructured":"Kyle, R. A. & Rajkumar, S. V. Multiple myeloma. Blood 111, 2962\u20132972 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc201031_CR6","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1038\/leu.2009.89","volume":"23","author":"M Dimopoulos","year":"2009","unstructured":"Dimopoulos, M. et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia 23, 1545\u20131556 (2009).","journal-title":"Leukemia"},{"key":"BFnrclinonc201031_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1634\/theoncologist.2009-0203","volume":"15","author":"H Ludwig","year":"2010","unstructured":"Ludwig, H. et al. Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist 15, 6\u201325 (2010).","journal-title":"Oncologist"},{"key":"BFnrclinonc201031_CR8","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1211\/0022357022241","volume":"55","author":"T Eriksson","year":"2003","unstructured":"Eriksson, T. et al. Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. J. Pharm. Pharmacol. 55, 1701\u20131706 (2003).","journal-title":"J. Pharm. Pharmacol."},{"key":"BFnrclinonc201031_CR9","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1517\/17425255.4.5.639","volume":"4","author":"E Terpos","year":"2008","unstructured":"Terpos, E., Roussou, M. & Dimopoulos, M. A. Bortezomib in multiple myeloma. Expert Opin. Drug Metab. Toxicol. 4, 639\u2013654 (2008).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"BFnrclinonc201031_CR10","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1177\/0091270007309563","volume":"47","author":"N Chen","year":"2007","unstructured":"Chen, N. et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J. Clin. Pharmacol. 47, 1466\u20131475 (2007).","journal-title":"J. Clin. Pharmacol."},{"key":"BFnrclinonc201031_CR11","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/j.1365-2141.2005.05519.x","volume":"129","author":"HE Oakervee","year":"2005","unstructured":"Oakervee, H. E. et al. PAD combination therapy (PS-341\/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br. J. Hematol. 129, 755\u2013762 (2005).","journal-title":"Br. J. Hematol."},{"key":"BFnrclinonc201031_CR12","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1517\/13543784.17.6.879","volume":"17","author":"J Sterz","year":"2008","unstructured":"Sterz, J. et al. The potential of proteasome inhibitors in cancer therapy. Expert Opin. Investig. Drugs 17, 879\u2013895 (2008).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"BFnrclinonc201031_CR13","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3324\/haematol.10759","volume":"9","author":"E Kastritis","year":"2007","unstructured":"Kastritis, E. et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Hematologica 9 2, 546\u2013549 (2007).","journal-title":"Hematologica"},{"key":"BFnrclinonc201031_CR14","doi-asserted-by":"crossref","unstructured":"Ludwig, H. et al. Bortezomib-doxorubicin-dexamethasone (BDD) in patients with acute light chain induced renal failure (ARF) in multiple myeloma (MM). Final results of a phase II study [abstract 3862]. Blood 114, 1486a (2009).","DOI":"10.1182\/blood.V114.22.3862.3862"},{"key":"BFnrclinonc201031_CR15","doi-asserted-by":"crossref","first-page":"1012a","DOI":"10.1182\/blood.V108.11.1012.1012","volume":"108","author":"D Weber","year":"2006","unstructured":"Weber, D. et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of 2 phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal function [abstract 3547]. Blood 108, 1012a (2006).","journal-title":"Blood"},{"issue":"Suppl.","key":"BFnrclinonc201031_CR16","first-page":"464s","volume":"26","author":"DM Weber","year":"2008","unstructured":"Weber, D. M. et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma patients with impaired renal function [abstract 8542]. J. Clin. Oncol. 26 (Suppl.), 464s (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201031_CR17","doi-asserted-by":"publisher","first-page":"1013a","DOI":"10.1182\/blood-2005-10-3949","volume":"108","author":"DE Reece","year":"2006","unstructured":"Reece, D. E. et al. Use of lenalidomide (Revlimid\u00ae) \u00b1 corticosteroids in relapsed\/refractory multiple myeloma patients with elevated baseline serum creatinine levels [abstract 3548]. Blood 108, 1013a (2006).","journal-title":"Blood"},{"key":"BFnrclinonc201031_CR18","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa070596","volume":"357","author":"DM Weber","year":"2007","unstructured":"Weber, D. M. et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N. Engl. J. Med. 357, 2133\u20132142 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201031_CR19","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa070594","volume":"357","author":"M Dimopoulos","year":"2007","unstructured":"Dimopoulos, M. et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N. Engl. J. Med. 357, 2123\u20132132 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201031_CR20","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/j.1365-2141.2007.06698.x","volume":"138","author":"R Niesvizky","year":"2007","unstructured":"Niesvizky, R. et al. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naive patients undergoing front-line lenalidomide and dexamethasone therapy. Br. J. Hematol. 138, 640\u2013643 (2007).","journal-title":"Br. J. Hematol."},{"key":"BFnrclinonc201031_CR21","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1038\/leu.2008.131","volume":"22","author":"MA Dimopoulos","year":"2008","unstructured":"Dimopoulos, M. A., Kastritis, E., Rosinol, L., Blad\u00e9, J. & Ludwig, H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 22, 1485\u20131493 (2008).","journal-title":"Leukemia"},{"key":"BFnrclinonc201031_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.blre.2008.07.003","volume":"23","author":"A Palumbo","year":"2009","unstructured":"Palumbo, A. et al. Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Blood Rev. 23, 87\u201393 (2009).","journal-title":"Blood Rev."},{"key":"BFnrclinonc201031_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","volume":"11","author":"SV Rajkumar","year":"2010","unstructured":"Rajkumar, S. V. et al. High-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 11, 29\u201337 (2010).","journal-title":"Lancet Oncol."},{"key":"BFnrclinonc201031_CR24","first-page":"517","volume":"79","author":"HC Rayner","year":"1991","unstructured":"Rayner, H. C., Haynes, A. P., Thompson, J. R., Russell, N. & Fletcher, J. Perspectives in multiple myeloma: survival, prognostic factors and disease complications in a single center between 1975 and 1988. Q. J. Med. 79, 517\u2013525 (1991).","journal-title":"Q. J. Med."},{"key":"BFnrclinonc201031_CR25","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1038\/sj.leu.2404801","volume":"21","author":"S Kumar","year":"2007","unstructured":"Kumar, S. et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 21, 2035\u20132042 (2007).","journal-title":"Leukemia"},{"key":"BFnrclinonc201031_CR26","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.bbmt.2009.02.011","volume":"15","author":"U Popat","year":"2009","unstructured":"Popat, U. et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol. Blood Marrow Transplant. 15, 718\u2013723 (2009).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"BFnrclinonc201031_CR27","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1182\/blood-2009-04-205013","volume":"114","author":"S Kumar","year":"2009","unstructured":"Kumar, S. et al. International Myeloma Working Group. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 114, 1729\u20131735 (2009).","journal-title":"Blood"},{"key":"BFnrclinonc201031_CR28","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.bbmt.2008.04.008","volume":"14","author":"T Mark","year":"2008","unstructured":"Mark, T. et al. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol. Blood Marrow Transplant. 14, 795\u2013798 (2008).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"BFnrclinonc201031_CR29","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/leu.2009.127","volume":"2","author":"S Giralt","year":"2009","unstructured":"Giralt, S. et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 2 3, 1904\u20131912 (2009).","journal-title":"Leukemia"},{"key":"BFnrclinonc201031_CR30","doi-asserted-by":"crossref","first-page":"a253","DOI":"10.1182\/blood.V114.22.253.253","volume":"114","author":"A Palumbo","year":"2009","unstructured":"Palumbo, A. et al. A phase III study to determine the efficacy and safety of lenalidomide in combination with melphalan and prednisone (MPR) in elderly patients with newly diagnosed multiple myeloma [abstract 613]. Blood 114, a253 (2009).","journal-title":"Blood"}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2010.31.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2010.31","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2010.31.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:05:36Z","timestamp":1684469136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2010.31"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,30]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["BFnrclinonc201031"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2010.31","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,30]]}}}